ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this regard, XN could enhance the therapeutic efficacy of imatinib via alleviating imatinib-induced autophagy; on the other hand, XN itself could also eliminate oncoprotein BCR-ABL and induce apoptosis, suggesting XN, at least, could serve as an imatinib sensitizer and an oncoprotein degrader in the treatment of CML.